We are live on ! Find out more
VRPX

Virpax Pharmaceuticals, Inc. Common Stock
VRPX

Delisted

VRPX was delisted on the 3rd of April, 2025.

Back to rankings

3 hedge funds and large institutions have $6.44K invested in Virpax Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% less funds holding

Funds holding: 15 → 3 (-12)

95% less capital invested

Capital invested by funds: $121K → $6.44K (-$114K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 12

Holders
3
Holders Change
-12
Holders Change %
-80%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$2.9K
2
SRCM
Signature Resources Capital Management
California
+$1.58K

Top Sellers

Rank Fund Capital Flow
1
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$32.3K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$21.2K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$20.2K
4
SSWM
Sheets Smith Wealth Management
North Carolina
-$16K
5
Renaissance Technologies
Renaissance Technologies
New York
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
1
Tower Research Capital (TRC)
New York
$6.17K +$2.9K +33 +132%
SRCM
2
Signature Resources Capital Management
California
$160 +$1.58K +18 +900%
Morgan Stanley
3
Morgan Stanley
New York
$64 – – –
Wells Fargo
4
Wells Fargo
California
$34 – – –
PA
5
Parallel Advisors
California
$4 – – –
PNC Financial Services Group
6
PNC Financial Services Group
Pennsylvania
– -$32.3K -404 Closed
Vanguard Group
7
Vanguard Group
Pennsylvania
– -$21.2K -265 Closed
Geode Capital Management
8
Geode Capital Management
Massachusetts
– -$20.2K -256 Closed
SSWM
9
Sheets Smith Wealth Management
North Carolina
– -$16K -200 Closed
Renaissance Technologies
10
Renaissance Technologies
New York
– -$10K -122 Closed
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
– -$5.59K -71 Closed
Northern Trust
12
Northern Trust
Illinois
– -$4.87K -61 Closed
TSS
13
Two Sigma Securities
New York
– -$3.74K -47 Closed
UBS Group
14
UBS Group
Switzerland
– -$2.12K -26 Closed
JP Morgan Chase
15
JP Morgan Chase
New York
– -$1.37K -17 Closed
Osaic Holdings
16
Osaic Holdings
Arizona
– -$768 -10 Closed
BlackRock
17
BlackRock
New York
– -$149 -2 Closed

VRPX Hedge Fund Activity: Q1 2024 in Review

3 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q1 2024, worth a combined $6.44K — down 95% from $121K a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of VRPX and 0 opened new positions — a net loss of 12 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $2.9K. The largest seller was PNC Financial Services Group, exiting entirely with an estimated $32.3K sold.

  • 3 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q1 2024, down from 15 in Q4 2023.
  • Funds reported $6.44K of Virpax Pharmaceuticals, Inc. Common Stock stock for Q1 2024, down 95% quarter-over-quarter.
  • 0 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 12 closed out, a net change of -12 holders.
  • The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Tower Research Capital (TRC), an estimated $2.9K added.
  • The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was PNC Financial Services Group, an estimated $32.3K sold.

Based on aggregated 13F filings for Q1 2024.